Back to top
more

Cytosorbents (CTSO)

(Delayed Data from NSDQ)

$0.80 USD

0.80
46,299

0.00 (0.12%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $0.82 +0.02 (2.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Cytosorbents Corporation [CTSO]

Reports for Purchase

Showing records 1 - 20 ( 183 total )

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 2

03/15/2024

Company Report

Pages: 6

Full Phase 3 Results at AATS Meeting in April; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 3

12/29/2023

Company Report

Pages: 6

Phase 3 Ticagrelor Removal Study Misses Primary Endpoint; Downgrade to Neutral With $1.00 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 12.50

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 4

12/28/2023

Company Report

Pages: 4

BUY: STAR-T Trial Update: Mixed Data. Increasing Our Risk (r) from 15% to 30%, Lowers Our Price Target from $10 to $4

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 5

12/14/2023

Company Report

Pages: 4

BUY: Raises $10M, Adds to Reported Q3 Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 6

11/15/2023

Company Report

Pages: 4

BUY: Post Covid Hangover- Adjusting Estimates, Price Target Goes to $10

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 7

11/10/2023

Company Report

Pages: 6

Major Clinical Readout Expected Around Year-End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 12.50

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 8

09/18/2023

Company Report

Pages: 5

BUY: Data on Ex Vivo Organ Perfusion in Recent Publication

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 9

08/02/2023

Company Report

Pages: 6

All Eyes on STAR-T Results Before Year-End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 12.50

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 10

08/02/2023

Company Report

Pages: 4

BUY: Reports 2nd Quarter Results - Pivotal Data by Year End

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 11

07/07/2023

Company Report

Pages: 5

BUY: CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 12

06/16/2023

Company Report

Pages: 5

BUY: DSMB Recommends Complete STAR-T No Modifications Needed

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 13

05/03/2023

Company Report

Pages: 6

STAR-T Results in 2H23 Could Be a Major Catalyst; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 12.50

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 14

05/03/2023

Company Report

Pages: 5

BUY: Reports 1st Quarter 2023

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 15

04/20/2023

Company Report

Pages: 5

BUY: STAR-T Trial Reaches 2nd Milestone at N

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 16

03/10/2023

Company Report

Pages: 5

BUY: Reports 4th Quarter and Full Year 2022 Results

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 17

03/10/2023

Company Report

Pages: 6

Returning to Growth in 2023; STAR-T Results By Year-End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 12.50

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 18

02/01/2023

Company Report

Pages: 5

BUY: Preliminary 4th Quarter Revenues: $9.4M

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 19

01/24/2023

Company Report

Pages: 5

BUY: The Canadians Are In Seven Sites For STAR-T

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 20

12/29/2022

Company Report

Pages: 5

BUY: Managing Cash - $5M Debt Financing

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party